---
document_datetime: 2025-12-02 06:32:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-teva.html
document_name: lamivudine-teva.html
version: success
processing_time: 0.1246772
conversion_datetime: 2025-12-28 18:39:07.997821
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Lamivudine Teva

[RSS](/en/individual-human-medicine.xml/66085)

##### Authorised

This medicine is authorised for use in the European Union

lamivudine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Lamivudine Teva](#more-information-on-lamivudine-teva-1196)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Lamivudine Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lamivudine Teva.

Expand section

Collapse section

## What is Lamivudine Teva?

Lamivudine Teva is a medicine that contains the active substance lamivudine. It is available as tablets (100 mg).

Lamivudine Teva is a 'generic medicine'. This means that Lamivudine Teva is similar to a 'reference medicine' already authorised in the European Union (EU) called Zeffix.

## What is Lamivudine Teva used for?

Lamivudine Teva is used to treat adult patients who have chronic (long term) hepatitis B (a disease of the liver due to an infection by the hepatitis B virus). It is used in patients with compensated liver disease (when the liver is damaged but functions normally), who also show signs that the virus is still multiplying, and have signs of liver damage (raised levels of the liver enzyme 'alanine aminotransferase' [ALT] and signs of damage when liver tissue is examined under a microscope). Because the hepatitis B virus can become resistant to Lamivudine Teva, the doctor should only consider prescribing Lamivudine Teva if other treatments that are less likely to lead to resistance cannot be used.

The medicine can only be obtained with a prescription.

## How is Lamivudine Teva used?

Treatment with Lamivudine Teva should be initiated by a doctor who has experience in the management of chronic hepatitis B. The recommended dose of Lamivudine Teva is 100 mg once a day. The dose needs to be lowered for patients who have problems with their kidneys. Lamivudine Teva is not suitable for patients who require doses below 100 mg. The duration of treatment depends on the patient's condition and response to treatment.

If the hepatitis B virus can still be found in the blood after six months of treatment, the doctor should consider changing treatment to reduce the risk of resistance. Patients infected with a virus that has the 'YMDD mutation' (a change in the virus's DNA that is often found after treatment with lamivudine) should take Lamivudine Teva in combination with another medicine against hepatitis B. For more information, please see the summary of product characteristics (also part of the EPAR).

## How does Lamivudine Teva work?

The active substance in Lamivudine Teva, lamivudine, is an antiviral agent belonging to the class of the nucleoside analogues. Lamivudine interferes with the action of a viral enzyme, DNA polymerase, which is involved in the formation of viral DNA. Lamivudine stops the virus making DNA and prevents it from multiplying and spreading.

## How has Lamivudine Teva been studied?

Because Lamivudine Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Zeffix. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefit and risk of Lamivudine Teva?

Because Lamivudine Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine.

## Why has Lamivudine Teva been approved?

The CHMP concluded that, in accordance with EU requirements, Lamivudine Teva has been shown to have comparable quality and to be bioequivalent to Zeffix. Therefore, the CHMP's view was that, as for Zeffix, the benefit outweighs the identified risk. The Committee recommended that Lamivudine Teva be given marketing authorisation.

## Other information about Lamivudine Teva

The European Commission granted a marketing authorisation valid throughout the European Union for Lamivudine Teva on 23 October 2009.

For more information about treatment with Lamivudine Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Lamivudine Teva : EPAR - Summary for the public

English (EN) (47.37 KB - PDF)

**First published:** 09/11/2009

**Last updated:** 29/05/2012

[View](/en/documents/overview/lamivudine-teva-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-462)

български (BG) (87.1 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/bg/documents/overview/lamivudine-teva-epar-summary-public_bg.pdf)

español (ES) (109.82 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/es/documents/overview/lamivudine-teva-epar-summary-public_es.pdf)

čeština (CS) (136.58 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/cs/documents/overview/lamivudine-teva-epar-summary-public_cs.pdf)

dansk (DA) (110.42 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/da/documents/overview/lamivudine-teva-epar-summary-public_da.pdf)

Deutsch (DE) (111.37 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/de/documents/overview/lamivudine-teva-epar-summary-public_de.pdf)

eesti keel (ET) (107.15 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/et/documents/overview/lamivudine-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (148.68 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/el/documents/overview/lamivudine-teva-epar-summary-public_el.pdf)

français (FR) (111.19 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/fr/documents/overview/lamivudine-teva-epar-summary-public_fr.pdf)

italiano (IT) (110.21 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/it/documents/overview/lamivudine-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (95.79 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/lv/documents/overview/lamivudine-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (133.58 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/lt/documents/overview/lamivudine-teva-epar-summary-public_lt.pdf)

magyar (HU) (133.13 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/hu/documents/overview/lamivudine-teva-epar-summary-public_hu.pdf)

Malti (MT) (89.95 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/mt/documents/overview/lamivudine-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (108.99 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/nl/documents/overview/lamivudine-teva-epar-summary-public_nl.pdf)

polski (PL) (138 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/pl/documents/overview/lamivudine-teva-epar-summary-public_pl.pdf)

português (PT) (125.44 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/pt/documents/overview/lamivudine-teva-epar-summary-public_pt.pdf)

română (RO) (133.81 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/ro/documents/overview/lamivudine-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (133.48 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/sk/documents/overview/lamivudine-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (130.51 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/sl/documents/overview/lamivudine-teva-epar-summary-public_sl.pdf)

Suomi (FI) (108.09 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/fi/documents/overview/lamivudine-teva-epar-summary-public_fi.pdf)

svenska (SV) (107.99 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

29/05/2012

[View](/sv/documents/overview/lamivudine-teva-epar-summary-public_sv.pdf)

## Product information

Lamivudine Teva : EPAR - Product Information

English (EN) (381.45 KB - PDF)

**First published:** 09/11/2009

**Last updated:** 07/06/2024

[View](/en/documents/product-information/lamivudine-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-38)

български (BG) (516.26 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/bg/documents/product-information/lamivudine-teva-epar-product-information_bg.pdf)

español (ES) (391.76 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/es/documents/product-information/lamivudine-teva-epar-product-information_es.pdf)

čeština (CS) (466.75 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/cs/documents/product-information/lamivudine-teva-epar-product-information_cs.pdf)

dansk (DA) (406.41 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/da/documents/product-information/lamivudine-teva-epar-product-information_da.pdf)

Deutsch (DE) (410.15 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/de/documents/product-information/lamivudine-teva-epar-product-information_de.pdf)

eesti keel (ET) (393.22 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/et/documents/product-information/lamivudine-teva-epar-product-information_et.pdf)

ελληνικά (EL) (525.93 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/el/documents/product-information/lamivudine-teva-epar-product-information_el.pdf)

français (FR) (400.53 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/fr/documents/product-information/lamivudine-teva-epar-product-information_fr.pdf)

hrvatski (HR) (450.33 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/hr/documents/product-information/lamivudine-teva-epar-product-information_hr.pdf)

íslenska (IS) (410.92 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/is/documents/product-information/lamivudine-teva-epar-product-information_is.pdf)

italiano (IT) (414.46 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/it/documents/product-information/lamivudine-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (500.61 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/lv/documents/product-information/lamivudine-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (462.32 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/lt/documents/product-information/lamivudine-teva-epar-product-information_lt.pdf)

magyar (HU) (478.58 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/hu/documents/product-information/lamivudine-teva-epar-product-information_hu.pdf)

Malti (MT) (595.78 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/mt/documents/product-information/lamivudine-teva-epar-product-information_mt.pdf)

Nederlands (NL) (387.32 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/nl/documents/product-information/lamivudine-teva-epar-product-information_nl.pdf)

norsk (NO) (394.89 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/no/documents/product-information/lamivudine-teva-epar-product-information_no.pdf)

polski (PL) (493.01 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/pl/documents/product-information/lamivudine-teva-epar-product-information_pl.pdf)

português (PT) (483.36 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/pt/documents/product-information/lamivudine-teva-epar-product-information_pt.pdf)

română (RO) (495.11 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/ro/documents/product-information/lamivudine-teva-epar-product-information_ro.pdf)

slovenčina (SK) (475.28 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/sk/documents/product-information/lamivudine-teva-epar-product-information_sk.pdf)

slovenščina (SL) (448.2 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/sl/documents/product-information/lamivudine-teva-epar-product-information_sl.pdf)

Suomi (FI) (400.02 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/fi/documents/product-information/lamivudine-teva-epar-product-information_fi.pdf)

svenska (SV) (365.57 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

07/06/2024

[View](/sv/documents/product-information/lamivudine-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0026 06/06/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Lamivudine Teva : EPAR - All Authorised presentations

English (EN) (15.76 KB - PDF)

**First published:** 09/11/2009

**Last updated:** 24/06/2020

[View](/en/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-737)

български (BG) (41.98 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/bg/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (16.45 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/es/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (34.54 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/cs/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (15.54 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/da/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (14.97 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/de/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (15.82 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/et/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (40.27 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/el/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (15.59 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/fr/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (34.72 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/hr/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (15.76 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/is/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (14.88 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/it/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (38.99 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/lv/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (39.22 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/lt/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (23.33 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/hu/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (33.11 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/mt/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (15.82 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/nl/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (15.73 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/no/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (34.91 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/pl/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (15.94 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/pt/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (35.86 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/ro/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (34.97 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/sk/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (34.3 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/sl/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (16.09 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/fi/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (15.83 KB - PDF)

**First published:**

09/11/2009

**Last updated:**

24/06/2020

[View](/sv/documents/all-authorised-presentations/lamivudine-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Lamivudine Teva Active substance lamivudine International non-proprietary name (INN) or common name lamivudine Therapeutic area (MeSH) Hepatitis B, Chronic Anatomical therapeutic chemical (ATC) code J05AF05

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Lamivudine Teva is indicated for the treatment of chronic hepatitis B in adults with:

- compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see in section 5.1).

## Authorisation details

EMA product number EMEA/H/C/001113

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Swensweg 5

Marketing authorisation issued 23/10/2009 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Lamivudine Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (140.19 KB - PDF)

**First published:** 29/05/2012

**Last updated:** 07/06/2024

[View](/en/documents/procedural-steps-after/lamivudine-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Lamivudine Teva : EPAR - Public assessment report

English (EN) (202.97 KB - PDF)

**First published:** 09/11/2009

**Last updated:** 09/11/2009

[View](/en/documents/assessment-report/lamivudine-teva-epar-public-assessment-report_en.pdf)

#### More information on Lamivudine Teva

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 07/06/2024

## Share this page

[Back to top](#main-content)